INS and Alzheimer disease: Synoptically, the presented evidence suggests that GLP-1 agonists do not affect Tau phosphatase activity and predominantly suppress Tau hyperphosphorylation by enhancing insulin-sensitivity and the Akt-driven inhibition of GSK-3β during AD (Figure 1).